Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer - PubMed

Review

Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer

G J Kolvenbag et al. Urology. 2001 Aug.

Abstract

Nonsteroidal antiandrogens are generally used in conjunction with castration as combined androgen blockade. However, the changing profile of patients with prostate cancer has made monotherapy with a nonsteroidal antiandrogen an attractive alternative therapeutic approach, offering potential quality-of-life benefits over conventional treatment modalities. Of available antiandrogens, monotherapy with bicalutamide has been most extensively evaluated. Combined data from 2 studies at a median follow-up time of 6.3 years revealed no statistically significant difference in overall survival between bicalutamide 150-mg monotherapy and castration in patients with nonmetastatic locally advanced disease. In patients with metastatic disease, there was a statistically significant difference (6 weeks) in overall survival in favor of castration. Bicalutamide monotherapy is associated with significant quality-of-life benefits (sexual interest and physical capacity), with preliminary data suggesting that the risk of osteoporosis may also be reduced by bicalutamide 150-mg monotherapy compared with castration. In general, bicalutamide is well tolerated, with a predictable adverse-effect profile. Breast pain (40%) and gynecomastia (49%) are the most common adverse events seen during monotherapy with this drug. In summary, the availability of bicalutamide 150-mg monotherapy broadens treatment options for men with locally advanced prostate cancer, offering a viable and attractive alternative to castration in this patient population. Ongoing studies will determine the role of bicalutamide in the treatment of localized disease.

Similar articles

• Antiandrogen monotherapy: indications and results.

  Iversen P. Iversen P. Urology. 2002 Sep;60(3 Suppl 1):64-71. doi: 10.1016/s0090-4295(02)01576-5. Urology. 2002. PMID: 12231053 Review.

• Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.

  Sciarra A, Cardi A, Di Silverio F. Sciarra A, et al. Urol Int. 2004;72(2):91-8. doi: 10.1159/000075960. Urol Int. 2004. PMID: 14963347 Review.

• Antiandrogen monotherapy in the management of advanced prostate cancer.

  Kaisary AV. Kaisary AV. Eur Urol. 1997;31 Suppl 2:14-9; discussion 24-7. doi: 10.1159/000474543. Eur Urol. 1997. PMID: 9074906

• The role of antiandrogen monotherapy in the treatment of prostate cancer.

  Anderson J. Anderson J. BJU Int. 2003 Mar;91(5):455-61. doi: 10.1046/j.1464-410x.2003.04026.x. BJU Int. 2003. PMID: 12603397 Review.

• Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.

  Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I. Iversen P, et al. J Urol. 2000 Nov;164(5):1579-82. J Urol. 2000. PMID: 11025708

Cited by

• Selected endocrine disrupting compounds (vinclozolin, flutamide, ketoconazole and dicofol): effects on survival, occurrence of males, growth, molting and reproduction of Daphnia magna.

  Haeba MH, Hilscherová K, Mazurová E, Bláha L. Haeba MH, et al. Environ Sci Pollut Res Int. 2008 May;15(3):222-7. doi: 10.1065/espr2007.12.466. Environ Sci Pollut Res Int. 2008. PMID: 18504841

• Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles.

  Park SJ, Kufareva I, Abagyan R. Park SJ, et al. J Comput Aided Mol Des. 2010 May;24(5):459-71. doi: 10.1007/s10822-010-9362-4. Epub 2010 May 9. J Comput Aided Mol Des. 2010. PMID: 20455005 Free PMC article.

• Value of endocrine therapy for early and locally advanced prostate cancer.

  Wirth MP, Froehner M. Wirth MP, et al. Drugs Aging. 2003;20(2):115-24. doi: 10.2165/00002512-200320020-00003. Drugs Aging. 2003. PMID: 12534312 Review.

• Synchronous bilateral breast cancer in a male patient following hormone therapy for prostate cancer.

  Kijima Y, Yoshinaka H, Hirata M, Umekita Y, Matsukita S, Arima T, Nakagawa M, Kumemura H, Hamada N, Kaneko K, Funasako Y, Natsugoe S. Kijima Y, et al. Int J Clin Oncol. 2009 Jun;14(3):249-53. doi: 10.1007/s10147-008-0824-9. Epub 2009 Jul 11. Int J Clin Oncol. 2009. PMID: 19593618

• The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment.

  Dueregger A, Heidegger I, Ofer P, Perktold B, Ramoner R, Klocker H, Eder IE. Dueregger A, et al. Nutrients. 2014 Oct 21;6(10):4491-519. doi: 10.3390/nu6104491. Nutrients. 2014. PMID: 25338271 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information